Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)
Primary Purpose
ST-segment Elevation Myocardial Infarction, Subclinical Carotid Atherosclerosis
Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Rosuvastatin
Rosuvastatin
Sponsored by
About this trial
This is an interventional treatment trial for ST-segment Elevation Myocardial Infarction focused on measuring CIMT, IVUS-VH, Coronary artery disease
Eligibility Criteria
Inclusion Criteria:
- STEMI,
- no prior treatment with statins and
- a non significant lesion in one of the two non-culprit coronary arteries. -
Exclusion Criteria:
- age below 18 or above 81 years,
- unconscious patients,
- serum creatinine > 176μmol/L,
- total-cholesterol > 7.0 mmol/l,
- hypothyroidism ((TSH > 1.5 x ULN (upper limit of normal)),
- current liver disease (ALAT > 2 x ULN),
- unexplained creatine kinase > 3 x ULN,
- alcohol or drug abuse within the last five years,
- prior myopathy or serious hypersensitivity reaction caused by statins,
- women with childbearing potential who were not using chemical or mechanical contraception,
- pregnant or breastfeeding women,
- history of malignancy unless a disease-free period of more than five years was present,
- patients with abnormal lung function test (LFT),
- participation in another investigational drug study less than four weeks before enrolment in the present study,
- treatment with cyclosporine or fibrates. -
Sites / Locations
- Department of Cardiology, Odense University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Rosuvastatin 5mg
Rosuvastatin 40mg
Arm Description
Rosuvastatin 5mg/day
Rosuvastatin 40mg/day
Outcomes
Primary Outcome Measures
change from baseline in mean CIMT
Average of the far wall of common and bulbus carotid artery
Secondary Outcome Measures
changes from baseline in max CIMT
change from baseline in mean common CIMT
change from baseline in max common CIMT
change from baseline in mean bulbus CIMT
change from baseline in max bulbus CIMT
change from baseline in lipid values
correlation between CIMT measurements and lipid values
correlation between CIMT measurements and plaque components evaluated by IVUS-VH
Full Information
NCT ID
NCT01203982
First Posted
September 15, 2010
Last Updated
September 16, 2010
Sponsor
Odense University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01203982
Brief Title
Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)
Official Title
Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima Media Thickness and Its Relation to Plaque Components of the Coronary Arteries in Patients With ST-Segment Elevation Acute Myocardial Infarction
Study Type
Interventional
2. Study Status
Record Verification Date
September 2010
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Odense University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study was to measure the effect of moderate and intensive lipid-lowering treatment with rosuvastatin on the carotid intima-media thickness (CIMT) as a surrogate marker of cardiovascular risk.
Detailed Description
The aim of this study was to measure the effect of moderate (5mg) and intensive (40mg) lipid-lowering treatment with rosuvastatin on the carotid intima-media thickness as a surrogate marker of cardiovascular risk and to obtain whether CIMT correlated with the plaque components in coronary arteries evaluated with Intravascular Ultrasound Virtual Histology (IVUS-VH).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ST-segment Elevation Myocardial Infarction, Subclinical Carotid Atherosclerosis
Keywords
CIMT, IVUS-VH, Coronary artery disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
87 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Rosuvastatin 5mg
Arm Type
Active Comparator
Arm Description
Rosuvastatin 5mg/day
Arm Title
Rosuvastatin 40mg
Arm Type
Active Comparator
Arm Description
Rosuvastatin 40mg/day
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin
Other Intervention Name(s)
Crestor
Intervention Description
Rosuvastatin 5mg/day for one year
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin
Other Intervention Name(s)
Crestor
Intervention Description
Rosuvastatin 40mg/day for one year
Primary Outcome Measure Information:
Title
change from baseline in mean CIMT
Description
Average of the far wall of common and bulbus carotid artery
Time Frame
baseline, 6month, 12 month
Secondary Outcome Measure Information:
Title
changes from baseline in max CIMT
Time Frame
baseline, 6month, 12 month
Title
change from baseline in mean common CIMT
Time Frame
baaseline, 6month 12 month
Title
change from baseline in max common CIMT
Time Frame
baseline, 6month 12month
Title
change from baseline in mean bulbus CIMT
Time Frame
Baseline, 6month 12 month
Title
change from baseline in max bulbus CIMT
Time Frame
baseline, 6month 12month
Title
change from baseline in lipid values
Time Frame
baseline, 6month 12month
Title
correlation between CIMT measurements and lipid values
Time Frame
Baseline, 6month 12 month
Title
correlation between CIMT measurements and plaque components evaluated by IVUS-VH
Time Frame
Baseline, 6month 12month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
81 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
STEMI,
no prior treatment with statins and
a non significant lesion in one of the two non-culprit coronary arteries. -
Exclusion Criteria:
age below 18 or above 81 years,
unconscious patients,
serum creatinine > 176μmol/L,
total-cholesterol > 7.0 mmol/l,
hypothyroidism ((TSH > 1.5 x ULN (upper limit of normal)),
current liver disease (ALAT > 2 x ULN),
unexplained creatine kinase > 3 x ULN,
alcohol or drug abuse within the last five years,
prior myopathy or serious hypersensitivity reaction caused by statins,
women with childbearing potential who were not using chemical or mechanical contraception,
pregnant or breastfeeding women,
history of malignancy unless a disease-free period of more than five years was present,
patients with abnormal lung function test (LFT),
participation in another investigational drug study less than four weeks before enrolment in the present study,
treatment with cyclosporine or fibrates. -
Facility Information:
Facility Name
Department of Cardiology, Odense University Hospital
City
Odense
State/Province
Fuenen
ZIP/Postal Code
5000
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)
We'll reach out to this number within 24 hrs